|
|||||
|
|
Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use |
|
| Authors: | Peter Rossing MD Rajiv Agarwal MD Stefan D. Anker MD Gerasimos Filippatos MD Bertram Pitt MD Luis M. Ruilope MD Vivian Fonseca MD Guillermo E. Umpierrez MD Maria Luiza Caramori MD Amer Joseph MBBS Marc Lambelet Dipl. Math Robert Lawatscheck MD George L. Bakris MD the FIDELIO-DKD FIGARO-DKD Investigators |
| Affiliation: | 1. Clinical Research, Steno Diabetes Center Copenhagen, Herlev, Denmark;2. Richard L. Roudebush VA Medical Center and Indiana University School of Medicine, Indianapolis, Indiana, USA;3. Department of Cardiology (CVK);4. Berlin Institute of Health Center for Regenerative Therapies;5. German Centre for Cardiovascular Research partner site Berlin, Charité – Universitätsmedizin, Berlin, Germany;6. National and Kapodistrian University of Athens, School of Medicine, Department of Cardiology, Attikon University Hospital, Athens, Greece;7. Department of Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan, USA;8. Cardiorenal Translational Laboratory and Hypertension Unit, Institute of Research imas12, Madrid, Spain CIBER-CV, Hospital Universitario 12 de Octubre, Madrid, Spain Faculty of Sport Sciences, European University of Madrid, Madrid, Spain;9. Section of Endocrinology, Tulane University Health Sciences Center, New Orleans, Louisiana, USA;10. Division of Endocrinology, Emory University, Atlanta, Georgia, USA;11. Department of Medicine and Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA;12. Cardiology and Nephrology Clinical Development, Bayer AG, Berlin, Germany;13. Chrestos Concept GmbH & Co. KG, Essen, Germany;14. Clinical Research, Bayer AG, Berlin, Germany;15. Department of Medicine, University of Chicago Medicine, Chicago, Illinois, USA |
| Abstract: | |
| Keywords: | |